Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04514523 · ClinicalTrials.gov registry record · NA

QBSAfe: A Novel Approach to Diabetes Management Focused on Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events

A NA study of Diabetes and Diabetes Mellitus, sponsored by Yale University.

Completed
Registry status
NA
Development phase
91
Enrollment target
3
Study locations

NCT04514523 is a NA study of Diabetes and Diabetes Mellitus that has completed, run by Yale University. The registered enrollment target is 91 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04514523, a NA study of Diabetes and Diabetes Mellitus, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
91 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to co-develop a toolkit (known as the QBSAfe toolkit) with patients, family caregivers, and clinicians that focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety for patients with diabetes mellitus.

Interventions

  • OTHER QBSAfe Toolkit

Study Locations (3)

Connecticut

  • Yale University - New Haven
  • Trinity Health of New England - Waterbury

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2020-04-28
Est. Completion 2020-09-22
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04514523

The ClinicalTrials.gov registry entry for NCT04514523 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which QBSAfe Toolkit is the first listed.

NCT04514523 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04514523 about?

NCT04514523 is a clinical study titled "QBSAfe: A Novel Approach to Diabetes Management Focused on Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events". The purpose of this study is to co-develop a toolkit (known as the QBSAfe toolkit) with patients, family caregivers, and clinicians that focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety for patients with diabetes mellit...

What is the current status of trial NCT04514523?

This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2020-04-28. Estimated completion is 2020-09-22.

What conditions does trial NCT04514523 study?

This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus.

What interventions are being tested in trial NCT04514523?

The interventions under investigation include: QBSAfe Toolkit (OTHER).

Who is sponsoring clinical trial NCT04514523?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04514523 being conducted?

This trial has 3 study locations across Connecticut, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.